# Judge — L4-TICK11-LIRA-TIRZ, iteration 2

Judge: Kimi K3 (Agent J). Did not write this increment. Mood: critic.
File reviewed in full: `src/content/comparisons/liraglutide-vs-tirzepatide.mdx` (working tree, 2026-09-02).
Prior verdict: `L4-TICK11-LIRA-TIRZ-iter1.md` (RETRY-WITH-NEW-PLAN, one fail item F1 + residuals R1/R2).

## Independent verification performed

- Read the full MDX (frontmatter + body), not a diff skim.
- PowerShell `Select-String -SimpleMatch` on the file for: `<5%`, `~8%`, `3x`, `3×`, `~40%`, `~30%`, `still being studied`, `2.5mg`, `2.5 mg`, `90%`, `superior`, `Superior`, `63%`, `28.7`, `22.7`, `TRIUMPH`, `OSA`, `REDEFINE`, `&lt;5%`. Positive control `SCALE` fired 19 hits — grep was live.
- Raw-`<` scan: parsed the file, excluded frontmatter (ends line 53), regex `<\d` over the **body** only — zero hits.
- `git diff --stat HEAD -- <file>`: `1 file changed, 78 insertions(+), 107 deletions(-)` — existing slug with commit history (`42078b6`, `2423083`, `d951b5e`). No new URL. Full diff vs HEAD inspected hunk-by-hunk; every change is inside the TICK11 scope.
- PMIDs: not re-efetched. Iter1 efetched all five independently (65,110 bytes) and topical-matched them; the quoted figures in the current file are byte-identical to what iter1 verified, and the iter2 diff touches no quoted number. Optional re-fetch waived per brief.

## Iter1 fail item

- **F1 (was CRITICAL, build-breaking): unescaped `(<5%)` at line 143 — PASS.**
  Line 143 now reads `few leading to discontinuation (&lt;5%) [surmount-2-pmid-37385275]`. `<5%` simple-match: zero hits. Body-wide `<\d` scan (frontmatter excluded): zero hits. The SURMOUNT-2 GI fact and its citation are **retained** — escaped, not deleted (see Gaming check). The MDX-as-JSX parse hazard documented in `.claude/rules/lessons.md` is cleared for this file.

## Iter1 residuals (scored)

- **R1 (was MED): superiority adjectives — PASS.** Overview line 57 "newer dual GIP/GLP-1 agonist **with superior efficacy**" → "is a dual GIP/GLP-1 agonist." Mechanism bullet "**Superior weight loss**" → "Weight-change results from SURMOUNT-1 and SURMOUNT-2." Remaining `superior`/`superiority` hits (lines 21, 131, 133, 220) are all the trials' own hypothesis-test language — "noninferior, not superior, to dulaglutide" and "P=0.01 / P=0.09 for superiority" — which the standing SURPASS-CVOT criterion *requires*. Not the banned adjective class.
- **R2 (was LOW): banned literals inside disavowals — PASS.** `~8%`, `3x`/`3×`, `~40%`, `~30%`: zero hits anywhere, including negations. The disavowals survive with polarity intact but numbers dropped: "does not convert kilograms into a mean percent" (line 110), "does not convert those schedules into an injections-per-month count" (FAQ + line 149), "does not compute a relative-efficacy ratio" (line 213). The trophies are gone; the refusals are not.

## Standing criteria (must not be traded away)

1. **SCALE in kg, no mean-percent conversion — PASS.** Line 110: −8.4 kg vs −2.8 kg (diff −5.6 kg; 95% CI −6.0 to −5.1); ≥5% 63.2%/27.1%; >10% 33.1%/10.6%; n=3731, 56 wk, no T2D. Matches iter1's independent efetch figure-for-figure.
2. **SURMOUNT-1 15 mg −20.9% vs −3.1%; no invented ≥10% — PASS.** Lines 116–121: 5/10/15 mg −15.0/−19.5/−20.9% vs −3.1% (treatment-regimen labelled where the abstract leads with it); ≥5% 91% (88–94) vs 35%; ≥20% 57% (53–61) vs 3%; explicit "the abstract does not publish a ≥10% percent; this page does not invent one." No `90%` anywhere.
3. **LEADER HR 0.87 (0.78–0.97) — PASS.** Line 131: n=9340, median 3.8 y, 608/4668 (13.0%) vs 694/4672 (14.9%), HR 0.87 (95% CI 0.78–0.97), `P&lt;0.001` still correctly escaped.
4. **SURPASS-CVOT HR 0.92, noninferior not superior — PASS.** Line 133: mITT 6586 vs 6579, 801 (12.2%) vs 862 (13.1%), HR 0.92 (95.3% CI 0.83–1.01), P=0.003 NI / P=0.09 sup, "Noninferior, not superior, to dulaglutide." `still being studied`: zero hits.
5. **Price rows retained — PASS.** Line 154: `~$1,300/month` / `~$1,000-1,200/month` present; TICK6-PRICE correctly untouched (takeaway 8 still defers cost ranking).
6. **No new URLs; no resurrected claims — PASS.** One existing file in the diff. `63%`, `28.7`, `22.7`, `TRIUMPH`, `OSA`, `REDEFINE`: zero hits.

## Gaming check

The escape was done the honest way: the SURMOUNT-2 discontinuation fact (`&lt;5%`) is still on the page with its citation — the implementer did not buy a green grep by deleting the sentence, which would have been over-strip to silence the gate and an auto-fail. R1 was fixed by neutralizing the adjective while keeping the fact (dual agonism, SURMOUNT results) rather than by scrubbing the section; R2 was fixed by rewording the disavowals, and — the part a gamer would have missed — the *refusals themselves* were preserved, so the page still declines the kg→% conversion, the injections-per-month count, and the relative-efficacy ratio instead of quietly dropping the guardrails along with the banned strings. Diff delta vs iter1's reviewed state is a handful of single-line rewordings, all inside the loop's scope; nothing was re-traded (price rows, LEADER/SURPASS-CVOT statistical language, and the no-≥10% refusal all survive). No gaming detected.

## Verdict

**KEEP.** The iter1 fail item is fixed the correct way, both residuals are resolved, and every standing criterion still passes against the current working tree.
Ratchet: append the keep row to `../ratchet/L4.md` (or `ratchet/L4-TICK11-LIRA-TIRZ.md` per conductor convention).
Conductor: per AGENTS.md §J I do not touch LOOP-TASKS.md — marking TICK11 done is yours, and the Verifier still owes the Wave 3 sole-occupant build (`REAL_BUILD_EXIT=0`) before this loop's evidence is complete.
